Hailed as the world’s first artificial pancreas, the hybrid closed-loop insulin delivery system helps make type 1 diabetes more manageable.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Approved by the FDA in late 2016, this new technology enables direct communication between the continuous glucose monitoring device and insulin pump to stabilize blood glucose at an unprecedented level. The technology replaces the “open loop” concept that requires patients to use information from their continuous glucose monitor to determine how much insulin to inject.
In this video, learn more about why the hybrid closed-loop insulin delivery system is No. 1 on Cleveland Clinic’s list of Top 10 Medical Innovations for 2018.